The role of antimicrobial peptides in cardiovascular physiology and disease

Biochemical and Biophysical Research Communications

Volumn 390, Issue 3, 2009, Pages 363-367

  Li, Yifeng ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Cardioprotection; Cathelicidin; Defensin; Inflammation

Indexed keywords

ALPHA DEFENSIN; CATESTATIN; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; DEFENSIN 1; DEFENSIN 2; DEFENSIN 3; ENKELYTIN; HUMAN NEUTROPHIL PEPTIDE 4; POLYPEPTIDE ANTIBIOTIC AGENT; PR 39; SECRETOLYTIN; UNCLASSIFIED DRUG; VASOSTATIN 1;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; INFLAMMATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SHORT SURVEY;

AMINO ACID SEQUENCE; ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CARDIOVASCULAR SYSTEM; CATTLE; HUMANS; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, SECONDARY;

ANIMALIA;

EID: 70449712571     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.10.002     Document Type: Short Survey

References (48)

1. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 415 (2002) 389-395
2. Hancock R.E., and Diamond G. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol. 8 (2000) 402-410
3. Hancock R.E. Peptide antibiotics. Lancet 349 (1997) 418-422
4. Brogden K.A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat. Rev. Microbiol. 3 (2005) 238-250
5. Pütsep K., Carlsson G., Boman H.G., and Andersson M. Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study. Lancet 360 (2002) 1144-1149
6. Brown K.L., and Hancock R.E. Cationic host defense (antimicrobial) peptides. Curr. Opin. Immunol. 18 (2006) 24-30
7. Ross R. Atherosclerosis - an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
8. Libby P. Inflammation and cardiovascular disease mechanisms. Am. J. Clin. Nutr. 83 (2006) 456S-460S
9. Young J.L., Libby P., and Schönbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb. Haemost. 88 (2002) 554-567
10. van der Wal A.C., Becker A.E., van der Loos C.M., and Das P.K. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 89 (1994) 36-44
11. Madsen T., Skou H.A., Hansen V.E., Fog L., Christensen J.H., Toft E., and Schmidt E.B. C-reactive protein, dietary n - 3 fatty acids, and the extent of coronary artery disease. Am. J. Cardiol. 88 (2001) 1139-1142
12. Kougias P., Chai H., Lin P.H., Yao Q., Lumsden A.B., and Chen C. Defensins and cathelicidins: neutrophil peptides with roles in inflammation, hyperlipidemia and atherosclerosis. J. Cell. Mol. Med. 9 (2005) 3-10
13. Panyutich A.V., Panyutich E.A., Krapivin V.A., Baturevich E.A., and Ganz T. Plasma defensin concentrations are elevated in patients with septicemia or bacterial meningitis. J. Lab. Clin. Med. 122 (1993) 202-207
14. Higazi A.A., Lavi E., Bdeir K., Ulrich A.M., Jamieson D.G., Rader D.J., Usher D.C., Kane W., Ganz T., and Cines D.B. Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells. Blood 89 (1997) 4290-4298
15. Bdeir K., Cane W., Canziani G., Chaiken I., Weisel J., Koschinsky M.L., Lawn R.M., Bannerman P.G., Sachais B.S., and Cines D.B. Defensin promotes the binding of lipoprotein(a) to vascular matrix. Blood 94 (1999) 2007-2019
16. Higazi A.A., Nassar T., Ganz T., Rader D.J., Udassin R., Bdeir K., Hiss E., Sachais B.S., Williams K.J., Leitersdorf E., and Cines D.B. The alpha-defensins stimulate proteoglycan-dependent catabolism of low-density lipoprotein by vascular cells: a new class of inflammatory apolipoprotein and a possible contributor to atherogenesis. Blood 96 (2000) 1393-1398
17. Kougias P., Chai H., Lin P.H., Yao Q., Lumsden A.B., and Chen C. Neutrophil antimicrobial peptide alpha-defensin causes endothelial dysfunction in porcine coronary arteries. J. Vasc. Surg. 43 (2006) 357-363
18. Higazi A.A., Barghouti I.I., and Abu-Much R. Identification of an inhibitor of tissue-type plasminogen activator-mediated fibrinolysis in human neutrophils. A role for defensin. J. Biol. Chem. 270 (1995) 9472-9477
19. Hamsten A., and Eriksson P. Fibrinolysis and atherosclerosis. Baillieres Clin. Haematol. 8 (1995) 345-363
20. Nassar H., Lavi E., Akkawi S., Bdeir K., Heyman S.N., Raghunath P.N., Tomaszewski J., and Higazi A.A. Alpha-defensin: link between inflammation and atherosclerosis. Atherosclerosis 194 (2007) 452-457
21. Joseph G., Tarnow L., Astrup A.S., Hansen T.K., Parving H.H., Flyvbjerg A., and Frystyk J. Plasma alpha-defensin is associated with cardiovascular morbidity and mortality in type 1 diabetic patients. J. Clin. Endocrinol. Metab. 93 (2008) 1470-1475
22. Tomasinsig L., and Zanetti M. The cathelicidins - structure, function and evolution. Curr. Protein Pept. Sci. 6 (2005) 23-34
23. Cabiaux V., Agerberth B., Johansson J., Homblé F., Goormaghtigh E., and Ruysschaert J.M. Secondary structure and membrane interaction of PR-39, a Pro + Arg-rich antibacterial peptide. Eur. J. Biochem. 224 (1994) 1019-1027
24. Boman H.G., Agerberth B., and Boman A. Mechanisms of action on Escherichia coli of cecropin P1 and PR-39, two antibacterial peptides from pig intestine. Infect. Immun. 61 (1993) 2978-2984
25. Zanetti M. The role of cathelicidins in the innate host defenses of mammals. Curr. Issues Mol. Biol. 7 (2005) 179-196
26. Shi J., Ross C.R., Leto T.L., and Blecha F. PR-39, a proline-rich antibacterial peptide that inhibits phagocyte NADPH oxidase activity by binding to Src homology 3 domains of p47 phox. Proc. Natl. Acad. Sci. USA 93 (1996) 6014-6018
27. Li J., Brown L.F., Laham R.J., Volk R., and Simons M. Macrophage-dependent regulation of syndecan gene expression. Circ. Res. 81 (1997) 785-796
28. Korthuis R.J., Gute D.C., Blecha F., and Ross C.R. PR-39, A proline/arginine-rich antimicrobial peptide, prevents postischemic microvascular dysfunction. Am. J. Physiol. 277 (1999) H1007-H1013
29. Hoffmeyer M.R., Scalia R., Ross C.R., Jones S.P., and Lefer D.J. PR-39, A potent neutrophil inhibitor, attenuates myocardial ischemia-reperfusion injury in mice. Am. J. Physiol. Heart Circ. Physiol. 279 (2000) H2824-H2828
30. Ikeda Y., Young L.H., Scalia R., Ross C.R., and Lefer A.M. PR-39, A proline/arginine-rich antimicrobial peptidem exerts cardioprotective effects in myocardial ischemia-reperfusion. Cardiovasc. Res. 49 (2001) 69-77
31. Bao J., Sato K., Li M., Gao Y., Abid R., Aird W., Simons M., and Post M.J. PR-39 and PR-11 peptides inhibit ischemia-reperfusion injury by blocking proteasome-mediated I kappa B alpha degradation. Am. J. Physiol. Heart Circ. Physiol. 281 (2001) H2612-H2618
32. Muinck E.D., Nagy N., Tirziu D., Murakami M., Gurusamy N., Goswami S.K., Ghatpande S., Engelman R.M., Simons M., and Das D.K. Protection against myocardial ischemia-reperfusion injury by the angiogenic Masterswitch protein PR 39 gene therapy: the roles of HIF1alpha stabilization and FGFR1 signaling. Antioxid. Redox Signal. 9 (2007) 437-445
33. Gaczynska M., Osmulski P.A., Gao Y., Post M.J., and Simons M. Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. Biochemistry 42 (2003) 8663-8670
34. Wu J., Parungo C., Wu G., Kang P.M., Laham R.J., Sellke F.W., Simons M., and Li J. PR39 inhibits apoptosis in hypoxic endothelial cells: role of inhibitor apoptosis protein-2. Circulation 109 (2004) 1660-1667
35. Dürr U.H., Sudheendra U.S., and Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim. Biophys. Acta 1758 (2006) 1408-1425
36. Sørensen O., Cowland J.B., Askaa J., and Borregaard N. An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma. J. Immunol. Methods 206 (1997) 53-59
37. Oren Z., Lerman J.C., Gudmundsson G.H., Agerberth B., and Shai Y. Structure and organization of the human antimicrobial peptide LL-37 in phospholipid membranes: relevance to the molecular basis for its non-cell-selective activity. Biochem. J. 341 (1999) 501-513
38. Edfeldt K., Agerberth B., Rottenberg M.E., Gudmundsson G.H., Wang X.B., Mandal K., Xu Q., and Yan Z.Q. Involvement of the antimicrobial peptide LL-37 in human atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1551-1557
39. Ciornei C.D., Tapper H., Bjartell A., Sternby N.H., and Bodelsson M. Human antimicrobial peptide LL-37 is present in atherosclerotic plaques and induces death of vascular smooth muscle cells: a laboratory study. BMC Cardiovasc. Disord. 6 (2006) 49
40. Lau Y.E., Bowdish D.M., Cosseau C., Hancock R.E., and Davidson D.J. Apoptosis of airway epithelial cells: human serum sensitive induction by the cathelicidin LL-37. Am. J. Respir. Cell. Mol. Biol. 34 (2006) 399-409
41. Berkestedt I., Nelson A., and Bodelsson M. Endogenous antimicrobial peptide LL-37 induces human vasodilatation. Br. J. Anaesth. 100 (2008) 803-809
42. H. Benachour, M. Zaiou, A. Samara, B. Herbeth, M.L. Pfister, D. Lambert, G. Siest, S. Visvikis-Siest, Association of human cathelicidin (hCAP-18/LL-37) gene expression with cardiovascular disease risk factors, Nutr. Metab. Cardiovasc. Dis. (2009), in press, doi:10.1016/j.numecd.2009.01.001.
43. Brogden K.A., Guthmiller J.M., Salzet M., and Zasloff M. The nervous system and innate immunity: the neuropeptide connection. Nat. Immunol. 6 (2005) 558-564
44. Lundy F.T., and Linden G.J. Neuropeptides and neurogenic mechanisms in oral and periodontal inflammation. Crit. Rev. Oral Biol. Med. 15 (2004) 82-98
45. El Karim I.A., Linden G.J., Orr D.F., and Lundy F.T. Antimicrobial activity of neuropeptides against a range of micro-organisms from skin, oral, respiratory and gastrointestinal tract sites. J. Neuroimmunol. 200 (2008) 11-16
46. Tasiemski A., Hammad H., Vandenbulcke F., Breton C., Bilfinger T.J., Pestel J., and Salzet M. Presence of chromogranin-derived antimicrobial peptides in plasma during coronary artery bypass surgery and evidence of an immune origin of these peptides. Blood 100 (2002) 553-559
47. Tota B., Angelone T., Mazza R., and Cerra M.C. The chromogranin A-derived vasostatins: new players in the endocrine heart. Curr. Med. Chem. 15 (2008) 1444-1451
48. Ginsburg I., and Koren E. Are cationic antimicrobial peptides also 'double-edged swords'?. Expert Rev. Anti Infect. Ther. 6 (2008) 453-462